Breaking News Instant updates and real-time market news.

SMSI

Smith Micro

$6.13

-0.18 (-2.85%)

, HEXO

HEXO Corp

$4.03

0.09 (2.28%)

08:45
09/03/19
09/03
08:45
09/03/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Smith Micro (SMSI) 14.50% +9.92, Hexo Corp (HEXO) 41.26% +3.93, Blue Apron (APRN) 85.94% +1.85, New Age Beverages (NBEV) 29.89% +1.62, Zoom Video Communications (ZM) 10.03% +1.62, Dillard's (DDS) 29.92% +1.47, DaVita (DVA) 1.79% +1.41, Village Farms International (VFF) 20.01% +1.34, Jumia Technologies (JMIA) 21.07% +1.19, and Parsley Energy (PE) 1.39% +1.14.

SMSI

Smith Micro

$6.13

-0.18 (-2.85%)

HEXO

HEXO Corp

$4.03

0.09 (2.28%)

APRN

Blue Apron

$6.83

-0.06 (-0.87%)

NBEV

New Age Beverages

$3.04

-0.065 (-2.09%)

ZM

Zoom Video

$91.71

0.93 (1.02%)

DDS

Dillard's

$58.76

-0.49 (-0.83%)

DVA

DaVita

$56.37

0.87 (1.57%)

VFF

Village Farms

$10.48

0.01 (0.10%)

JMIA

Jumia Technologies

$11.11

0.32 (2.97%)

PE

Parsley Energy

$17.93

-0.1 (-0.55%)

  • 03

    Sep

  • 04

    Sep

  • 05

    Sep

  • 10

    Sep

  • 10

    Sep

  • 10

    Sep

  • 11

    Sep

  • 11

    Sep

  • 16

    Sep

  • 12

    Nov

SMSI Smith Micro
$6.13

-0.18 (-2.85%)

07/19/19
RILY
07/19/19
INITIATION
Target $5
RILY
Buy
B. Riley FBR starts Smith Micro with a Buy rating, $5 price target
B. Riley FBR analyst Josh Nichols initiated coverage of Smith Micro Software with a Buy rating and $5 price target. The company has undergone a "significant" transformation over the past few years, and now has a lean operating cost structure along with a suite of "innovative value-added" solutions that leverage its mobile expertise and carrier relationships, Nichols tells investors in a research note. The analyst expects Smith Micro's operating margins and free cash flow generation to "improve rapidly" given the trajectory of revenue growth and inherent leverage in the asset-light business. He models 36% revenue growth in 2019 and EBITDA margin expansion through 2020.
07/19/19
RILY
07/19/19
INITIATION
Target $5
RILY
Buy
Smith Micro initiated with a Buy at B. Riley FBR
B. Riley FBR started Smith Micro Software with a Buy rating and $5 price target. The company is transformed with "innovative" digital services, the firm contends.
10/01/18
ROTH
10/01/18
INITIATION
Target $4
ROTH
Buy
Smith Micro initiated with a Buy at Roth Capital
Roth Capital analyst Scott Searle started Smith Micro with a Buy rating and $4 price target. The analyst notes that over the past 18 months, Smith Micro has undergone a significant overhaul in cost structure, focus, and growth vectors. More specifically, the company has engineered a product turnaround in its visual voicemail business, while investing in location-based services, he points out, adding that he believes location represents a $1B-plus TAM in the U.S.
04/08/19
CHDN
04/08/19
INITIATION
Target $5
CHDN
Buy
Smith Micro initiated with a Buy at Chardan
Chardan analyst James McIlree initiated Smith Micro with a Buy and $5 price target.
HEXO HEXO Corp
$4.03

0.09 (2.28%)

06/14/19
CIBC
06/14/19
DOWNGRADE
CIBC
Neutral
HEXO Corp downgraded to Neutral from Outperformer at CIBC
CIBC analyst John Zamparo downgraded HEXO Corp to Neutral from Outperformer, stating that the company's FY20 revenue guidance of $400M depends on a smooth industry launch of derivative products, which he thinks is in doubt. He lowered his price target on HEXO shares to C$8.50 from C$9.50.
06/25/19
OPCO
06/25/19
DOWNGRADE
OPCO
Perform
HEXO Corp downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Rupesh Parikh downgraded HEXO Corp to Perform from Outperform as he now sees a more balanced outlook for the shares primarily driven by greater gross margin pressures than he initially envisioned, which is impacted by the potential for pricing pressures going forward and delays on the advanced products front. With his updated forecasts and incorporating Newstrike, the analyst now views shares as more fairly valued.
04/25/19
DESJ
04/25/19
INITIATION
DESJ
Buy
HEXO Corp initiated with a Buy at Desjardins
04/25/19
DESJ
04/25/19
INITIATION
DESJ
Buy
Desjardins initiates HEXO Corp, Canopy Growth, Aurora Cannabis with a Buy
Desjardins analyst John Chu initiated HEXO Corp (HEXO), Canopy Growth (CGC), and Aurora Cannabis (ACB) with a Buy rating and respective price targets of C$14, C$74, and C$16.50 as part of a broad research note, saying the "hype" around legalization of adult-use cannabis in Canada remains strong in spite of "underwhelming" early months of sales. The analyst attributes the challenges to ramp-up, logistical and distribution issues, but expects investors to consider the opportunity as a "global" one. Chu believes that "major" consumer packaged goods companies like Constellation (STZ), InBev (BUD), and Altria (MO), as well as retailers like Walgreens (WBA), CVS (CVS), and Rite Aid (RAD) should "help push cannabis and hemp into the mainstream."
APRN Blue Apron
$6.83

-0.06 (-0.87%)

11/15/18
STFL
11/15/18
NO CHANGE
Target $1.5
STFL
Hold
Blue Apron price target lowered to $1.50 from $2.00 at Stifel
Stifel analyst Scott Devitt noted that Blue Apron's Q3 revenue came in below estimates while its adjusted EBITDA beat expectations. The company also guided to revenue and active customers being down year-over-year in FY19, due to plans to rationalize its marketing spend and streamline its product development efforts to focus primarily on its most loyal users. Devitt, who thinks the reduced marketing and product development spending limits visibility into near-term growth potential, lowered his price target on Blue Apron shares to $1.50 from $2.00 and keeps a Hold rating on the stock.
11/15/18
LEHM
11/15/18
NO CHANGE
Target $1.25
LEHM
Equal Weight
Blue Apron price target lowered to $1.25 from $2.50 at Barclays
Barclays analyst Ross Sandler halved his price target for Blue Apron Holdings to $1.25 following the company's Q3 results. The analyst says that while he's encouraged by the progress the company is seeing in transitioning its model, he remains on the sidelines until the key financial metrics improve. He keeps an Equal Weight rating on the shares.
11/15/18
GUGG
11/15/18
DOWNGRADE
GUGG
Neutral
Blue Apron downgraded to Neutral from Buy at Guggenheim
11/15/18
11/15/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Blue Apron (APRN) downgraded to Neutral from Buy at Guggenheim with analyst Michael Graham saying the company's net loss of 71K customers was higher than anticipated even though EBITDA came in higher than expected. 2. Horizon Pharma (HZNP) downgraded to Neutral from Buy at Mizuho with analyst Irina Koffler saying after she spoke with management about planned investments in teprotumumab pre-launch and the Mirror trial, she reduced her 2019 forecasts for Krystexxa and Actimmune to below consensus. 3. Cabot Oil & Gas (COG) downgraded to Hold from Buy at Tudor Pickering. 4. Hawaiian Electric (HE) downgraded to Underperform from Neutral at BofA/Merrill with analyst Julien Dumoulin-Smith citing strong relative share performance on investor activism. 5. PG&E (PCG) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Stephen Byrd saying he sees an "unprecedented" level of uncertainty given that there is currently no liability cap that would be applied to 2018 wildfires. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
NBEV New Age Beverages
$3.04

-0.065 (-2.09%)

07/22/19
NORL
07/22/19
DOWNGRADE
Target $5
NORL
Market Perform
Northland downgrades New Age Beverages on 'more realistic' estimates
As previously reported, Northland analyst Mike Grondahl downgraded New Age Beverages to Market Perform from Outperform after having lowered his estimates for the second half of the year to reflect a "more realistic" ramp of revenues and adjusted EBITDA. The analyst, who lowered his 2019 revenue estimate to $283M from $320M, cut his price target on the stock to $5 from $8.
07/22/19
NORL
07/22/19
DOWNGRADE
Target $5
NORL
Market Perform
New Age Beverages downgraded to Market Perform from Outperform at Northland
Northland analyst Mike Grondahl downgraded New Age Beverages to Market Perform from Outperform and lowered his price target on the stock to $5 from $8.
02/13/19
NORL
02/13/19
NO CHANGE
NORL
Outperform
Northland taking 'conservative' view of New Age Beverages' 2019 results
Northland analyst Mike Grondahl said in a note prior to the open that he believes the fact that new shelf space for larger retailers is generally not available until March/April/May of 2019 presents a challenge to Q$ revenues and earnings for New Age Beverages. Also noting that shipping of new CBD products "remains in limbo due to uncertainty from the FDA," Grondahl lowered his estimates and said he is taking a "conservative look" at 2019 for the company. However, he continues to believe New Age is well positioned for the next few years and keeps an Outperform rating on the shares.
06/10/19
COMP
06/10/19
INITIATION
Target $9
COMP
Buy
New Age Beverages initiated with a Buy at Compass Point
Compass Point analyst Rommel Dionsio started New Age Beverages with a Buy rating and $9 price target.
ZM Zoom Video
$91.71

0.93 (1.02%)

07/12/19
07/12/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Slack Technologies (WORK) and Zoom Video (ZM) were initiated with an Overweight at Stephens. 2. Fate Therapeutics (FATE) initiated with an Outperform at Oppenheimer. 3. Ameris Bancorp (ABCB) initiated with an Outperform at Raymond James. 4. TriCo Bancshares (TCBK) initiated with a Neutral at Piper Jaffray. 5. Axalta Coating (AXTA) initiated with a Buy at Berenberg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/22/19
SPHN
08/22/19
INITIATION
Target $115
SPHN
Overweight
Zoom Video assumed with an Overweight at Stephens
Stephens analyst Ryan MacWilliams assumed coverage of Zoom Video with an Overweight rating and $115 price target.
07/12/19
WBLR
07/12/19
NO CHANGE
WBLR
Zoom Video growth still in 'early innings,' says William Blair
William Blair analyst Bhavan Suri says he left meeting with Zoom Video Communications' head of investor relations with reinforced confidence in the company's positioning and ability to continue gaining share in the market. Zoom is benefiting from a secular shift to video communications, which is still in the "early innings," Suri tells investors in a research note. He believes Zoom's "robust" growth and "best-in-class" operating metrics should continue "for years to come." The analyst keeps an Outperform rating on the shares.
07/11/19
SPHN
07/11/19
INITIATION
Target $115
SPHN
Overweight
Zoom Video initiated with an Overweight at Stephens
Stephens analyst Dmitry Netis initiated Zoom Video with an Overweight rating and $115 price target, citing his view that Zoom's modern approach to video "is driving a fundamental change in the user consumption model." He also believes continued share gains, new product launches, growing penetration and international expansion give Zoom a long growth runway.
DDS Dillard's
$58.76

-0.49 (-0.83%)

08/16/19
JPMS
08/16/19
NO CHANGE
Target $37
JPMS
Underweight
Dillard's price target lowered to $37 from $54 at JPMorgan
JPMorgan analyst Matthew Boss lowered his price target for Dillard's to $37 from $54 following the company's "material" Q2 miss. The analyst sees tougher comps ahead for Dillard's and keeps an Underweight rating on the shares. Importantly, the press release included no commentary on Q2 business results versus Q2 of last year when CEO Dillard cited "is encouraging YTD improvement as we head into the important back half of the year," Boss points out in a research note to investors.
07/11/19
WEDB
07/11/19
UPGRADE
WEDB
Neutral
Dillard's upgraded to Neutral from Underperform at Wedbush
08/14/19
WEDB
08/14/19
NO CHANGE
Target $56
WEDB
Neutral
Dillard's price target lowered to $56 from $62 at Wedbush
Wedbush analyst Jen Redding lowered her price target for Dillard's to $56 from $62 as she leans cautiously into Q2 earnings. Her Promotional, Search, and Big Data models are highlighting light demand trends and increases in markdown rates, compounded by challenging mall traffic numbers in the second quarter, she contends, adding that the Big Data read for Dillard's is negative with increased discounting, deterioration in pricing trends, and inventories responding in kind. Redding reiterates a Neutral rating on the shares.
07/11/19
07/11/19
UPGRADE
Target $62

Neutral
Dillard's upgraded to Neutral at Wedbush as promotional data shows stabilization
As previously reported, Wedbush analyst Jen Redding upgraded Dillard's to Neutral from Underperform as promotional levels stabilize, according to Search Trends and her Promo Tracker, and valuation strikes her as reasonable. The analyst notes that more recent promotional data shows stabilization in markdown trends, as promotions over the July 4th holiday approximated depth and duration levels year over year. As promotional levels stabilize, search trends show upward momentum in demand by about 740 bps in June from May, with early July data still stronger, coupled with an uptick in recent Form 4 insider purchasing, she adds. Redding also raised her price target on the shares to $62 from $54.
DVA DaVita
$56.37

0.87 (1.57%)

07/26/19
BARD
07/26/19
DOWNGRADE
Target $65
BARD
Neutral
DaVita downgraded to Neutral at Baird
As reported previously, Baird analyst Matthew Gillmor downgraded DaVita to Neutral from Outperform as key catalysts that supported his thesis have played out, including stock buybacks and the DMG sale. Despite a discount valuation, fundamentals are slowing and there are a lot of regulatory and reimbursement uncertainties facing the company. Gillmor lowered his price target to $65 from $70 on DaVita shares.
07/26/19
BARD
07/26/19
DOWNGRADE
Target $65
BARD
Neutral
DaVita downgraded to Neutral from Outperform at Baird
Baird analyst Matthew Gillmor downgraded DaVita to Neutral from Outperform and lowered his price target for the shares to $65 from $70.
01/09/19
RBCM
01/09/19
NO CHANGE
Target $65
RBCM
Sector Perform
DaVita price target lowered to $65 from $78 at RBC Capital
RBC Capital analyst Frank Morgan lowered his price target on DaVita to $65 and also reduced his FY19 EPS view to $3.93 from $4.12 after its management provided initial FY19 operating income outlook of $1.54B-$1.64B relative to consensus of $1.62B. The analyst notes that the company's near term is likely to be impacted by "industry headline risk, potential margin pressures due to increased scrutiny of dialysis rates, and ongoing labor cost growth", but sees dialysis as a "steady, stable, defensive industry over the long term, with predictable patient volumes and strong cash flows".
02/15/19
BARD
02/15/19
NO CHANGE
Target $70
BARD
Outperform
DaVita price target lowered to $70 from $90 at Baird
Baird analyst Matthew Gillmor lowered his price target on DaVita to $70 from $90 and acknowledged it remains a controversial stock. The analyst said underlying demand appears to be slowing, but that valuation is undemanding and already reflects significant earnings risk. Although Gillmor said his enthusiasm for DaVita has waned recently, he believes it still has a favorable setup and thus maintained his Outperform rating on the shares.
VFF Village Farms
$10.48

0.01 (0.10%)

07/22/19
CHLM
07/22/19
INITIATION
Target $30
CHLM
Buy
Village Farms initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Eric Des Lauriers initiated Village Farms with a Buy rating and a price target of $30, saying the company is becoming a "dominant" cannabis cultivator and has a large opportunity in U.S. hemp space. The analyst notes that Village Farms is exceeding cannabis yield and quality expectations and believes the company has a low-cost path to becoming a dominant cultivator, with potential to "far exceed" consensus estimates beginning in 2020.
06/13/19
ROTH
06/13/19
INITIATION
Target $25
ROTH
Buy
Village Farms initiated with a Buy at Roth Capital
Roth Capital analyst Scott Fortune started coverage of Village Farms with a Buy rating and $25 price target. The analyst notes that the company is converting its 10.6M sq. ft. tomato greenhouse infrastructure in North America, to new profitable cannabis/hemp cultivation. Established distribution and relationships with the biggest U.S. retailers allow potential new CBD product sales, he contends, adding that Village Farms can easily convert into cannabis cultivation once federally legal in the U.S. and Mexico.
JMIA Jumia Technologies
$11.11

0.32 (2.97%)

08/21/19
RBCM
08/21/19
UPGRADE
Target $30
RBCM
Outperform
Jumia Technologies upgraded to Outperform from Sector Perform at RBC Capital
RBC Capital analyst Mark Mahaney upgraded Jumia Technologies to Outperform but lowered his price target to $30 from $40.
08/21/19
STFL
08/21/19
NO CHANGE
Target $28
STFL
Buy
Jumia's report doesn't alter Stifel view that 'best days' still to come
Stifel analyst Scott Devitt said Jumia reported "mixed" Q2 results, including gross merchandise volume growth of 69% that was "strong" although it was below expectations. Year-over-year revenue growth of 58% was also slightly below his expectations, but Jumia "continued on its gradual path to profitability," said Devitt. Regarding the company's findings from a review of several JForce agents involved in improper sales practices in Nigeria as well as improper orders that were placed through the JForce program, Devitt said the impact from these inappropriate activities is relatively small and "better-than-feared," adding that fraudulent activity in non-developed markets is "something all marketplaces deal with." He still sees Jumia's long-term opportunity as highly attractive and "nothing in today's report changes our view," stated Devitt, who keeps a Buy rating on the stock. However, he trimmed his price target on Jumia shares to $28 from $34.
08/22/19
RAJA
08/22/19
NO CHANGE
Target $23
RAJA
Outperform
Jumia Technologies price target lowered to $23 from $36 at Raymond James
Raymond James analyst Aaron Kessler lowered his price target for Jumia Technologies to $23 from $36 but maintained an Outperform rating following the company's "mixed" second quarter results. In a research note to investors, Kessler says that while results were softer than anticipated, he maintains a positive outlook on shares and expects robust eCommerce growth in Africa. He also feels Jumia has significant potential beyond its core marketplaces including payments and other services.
08/21/19
08/21/19
UPGRADE
Target $30

Outperform
Jumia Technologies upgraded to Outperform at RBC Capital on attractive valuation
As previously reported, RBC Capital analyst Mark Mahaney upgraded Jumia Technologies to Outperform but lowered his price target to $30 from $40. The analyst notes the company's Q2 results were mixed with above-consensus gross merchandise volume and accelerating active customer growth but with less than expected EBITDA. Mahaney adds that while the stock price declined by over 16% after today's report, the company's fundamental trends were overall positive. Given the improving fundamentals and "robust growth potential", the analyst sees the valuation on Jumia shares as "attractive".
PE Parsley Energy
$17.93

-0.1 (-0.55%)

08/27/19
08/27/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Parsley Energy (PE) initiated with a Buy at MKM Partners. 2. Store Capital (STOR) initiated with a Buy at Deutsche Bank. 3. Zebra Technologies (ZBRA) initiated with an Overweight at Atlantic Equities. 4. BorgWarner (BWA) initiated with a Buy at Nomura Instinet. 5. CleanSpark (CLSK) initiated with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/27/19
08/27/19
INITIATION
Target $26

Buy
Parsley Energy initiated with a Buy at MKM Partners
As previously reported, MKM Partners analyst John Gerdes initiated Parsley Energy with a Buy rating and a price target of $26. The analyst notes that his forecast for 2019 production at 140.9 MBOE/D is above the high end of the company's 134-139 MBOE/D guidance and also points to Parsley Energy's cash operating margin being 30% above the industry mean thanks to its 20% lower per unit cash expense and a higher oil composition.
08/26/19
MKMP
08/26/19
INITIATION
MKMP
Buy
Parsley Energy initiated with a Buy at MKM Partners
07/15/19
JEFF
07/15/19
DOWNGRADE
Target $7
JEFF
Hold
Callon Petroleum downgraded to Hold on cash flow challenges at Jefferies
Jefferies analyst Mark Lear downgraded Callon Petroleum to Hold from Buy and lowered his price target for the shares to $7 from $11. The analyst believes the company will be challenged to deliver free cash flow. His favorite ways to play the Midland are Diamondback Energy (FANG), Parsley Energy (PE), and Concho Resources (CXO).

TODAY'S FREE FLY STORIES

NET

Cloudflare

$17.96

(0.00%)

, AMZN

Amazon.com

$1,837.49

-6 (-0.33%)

07:40
09/15/19
09/15
07:40
09/15/19
07:40
On The Fly
Opening Day: Cloudflare jumps in market debut »

Shares of Cloudflare…

NET

Cloudflare

$17.96

(0.00%)

AMZN

Amazon.com

$1,837.49

-6 (-0.33%)

MSFT

Microsoft

$137.21

-0.33 (-0.24%)

STSA

Satsuma Pharmaceuticals

$16.61

(0.00%)

SWTX

SpringsWorks Therapeutics

$22.75

(0.00%)

SDC

SmileDirectClub

$18.68

1.8 (10.66%)

TXG

10x Genomics

$53.80

0.85 (1.61%)

PTON

Peloton

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

NVST

Envista

$0.00

(0.00%)

XGN

Exagen

$0.00

(0.00%)

DDOG

Datadog

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

NDAQ

Nasdaq

$99.51

0.5 (0.51%)

DHR

Danaher

$141.02

-0.84 (-0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

  • 17

    Sep

  • 17

    Sep

  • 27

    Oct

  • 07

    Nov

  • 18

    Sep

  • 19

    Sep

  • 26

    Sep

04:55
09/15/19
09/15
04:55
09/15/19
04:55
Conference/Events
SunTrust retail/consumer goods analysts to hold a dinner meeting »

Retail/Consumer Goods…

ABT

Abbott

$84.25

-0.96 (-1.13%)

, ADPT

Adaptive Biotechnologies

$43.28

3.49 (8.77%)

13:22
09/14/19
09/14
13:22
09/14/19
13:22
Conference/Events
William Blair diagnostic products/med tech analyst to hold a group luncheon »

Diagnostic Products &…

ABT

Abbott

$84.25

-0.96 (-1.13%)

ADPT

Adaptive Biotechnologies

$43.28

3.49 (8.77%)

BDX

Becton Dickinson

$260.68

-1.41 (-0.54%)

COO

Cooper Companies

$301.95

-3 (-0.98%)

EXAS

Exact Sciences

$106.72

-1.99 (-1.83%)

GH

Guardant Health

$77.54

0.49 (0.64%)

NEO

NeoGenomics

$21.34

-1.22 (-5.41%)

LMNX

Luminex

$22.62

0.1 (0.44%)

HAE

Haemonetics

$125.55

-0.31 (-0.25%)

STAA

STAAR Surgical

$29.21

0.415 (1.44%)

QGEN

Qiagen

$33.97

-0.105 (-0.31%)

NVTA

Invitae

$21.70

-0.2 (-0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 18

    Sep

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 25

    Sep

  • 27

    Sep

  • 13

    Nov

  • 05

    Dec

CRTO

Criteo

, TWTR

Twitter

13:19
09/14/19
09/14
13:19
09/14/19
13:19
Conference/Events
FBN Securities Tech/Internet analyst to hold a group luncheon »

Technology & Internet…

CRTO

Criteo

TWTR

Twitter

SNAP

Snap

GOOGL

Alphabet Class A

FB

Facebook

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 17

    Sep

  • 20

    Sep

  • 24

    Sep

  • 27

    Oct

T

AT&T

$37.90

-0.46 (-1.20%)

09:06
09/14/19
09/14
09:06
09/14/19
09:06
Periodicals
AT&T stock already benefiting from activist involvement, Barron's says »

AT&T 's board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

DIS

Disney

$138.00

0.44 (0.32%)

, NFLX

Netflix

$294.00

5.08 (1.76%)

09:04
09/14/19
09/14
09:04
09/14/19
09:04
Periodicals
Consumers might not be as in love with Apple TV+ as Wall Street, Barron's says »

Following Apple's…

DIS

Disney

$138.00

0.44 (0.32%)

NFLX

Netflix

$294.00

5.08 (1.76%)

AAPL

Apple

$218.71

-4.4 (-1.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Oct

UAL

United Airlines

$91.37

1.99 (2.23%)

08:58
09/14/19
09/14
08:58
09/14/19
08:58
Periodicals
United Airlines could get boost after short squeeze, Barron's says »

United Airlines stock has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

BAC

Bank of America

$30.12

0.44 (1.48%)

08:55
09/14/19
09/14
08:55
09/14/19
08:55
Periodicals
Bank of America stock worth betting on, Barron's says »

Amid talk of a coming…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

TPR

Tapestry

$25.16

-0.43 (-1.68%)

08:49
09/14/19
09/14
08:49
09/14/19
08:49
Periodicals
Coach parent's turnaround could be coming, Barron's says »

Even in a rough year for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UHAL

Amerco

$379.63

4.21 (1.12%)

08:45
09/14/19
09/14
08:45
09/14/19
08:45
Periodicals
U-Haul parent stock 'a better-kept secret,' Barron's says »

Amerco (UHAL), owner of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CP

Canadian Pacific

$228.59

-1.38 (-0.60%)

, CNI

Canadian National

$92.13

-0.31 (-0.34%)

08:41
09/14/19
09/14
08:41
09/14/19
08:41
Periodicals
Railroad stocks struggling as challenges increase, Barron's says »

North American railroads…

CP

Canadian Pacific

$228.59

-1.38 (-0.60%)

CNI

Canadian National

$92.13

-0.31 (-0.34%)

UNP

Union Pacific

$171.49

3.81 (2.27%)

CSX

CSX

$72.50

0.96 (1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

MO

Altria Group

$42.01

-0.77 (-1.80%)

, BTI

British American Tobacco

$36.76

-1.21 (-3.19%)

08:06
09/14/19
09/14
08:06
09/14/19
08:06
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

MO

Altria Group

$42.01

-0.77 (-1.80%)

BTI

British American Tobacco

$36.76

-1.21 (-3.19%)

IMBBY

Imperial Brands

$0.00

(0.00%)

PM

Philip Morris

$73.01

-1.89 (-2.52%)

REGI

Renewable Energy

$15.90

0.57 (3.72%)

PSX

Phillips 66

$102.77

0.66 (0.65%)

MPC

Marathon Petroleum

$53.29

0.1 (0.19%)

VLO

Valero

$85.53

1.84 (2.20%)

EVA

Enviva

$31.21

0.06 (0.19%)

AMTX

Aemetis

$1.00

0.14 (16.28%)

PEIX

Pacific Ethanol

$0.78

0.0322 (4.29%)

GPP

Green Plains Partners

$13.18

0.17 (1.31%)

DK

Delek US

$35.91

-0.6 (-1.64%)

HFC

HollyFrontier

$51.41

0.71 (1.40%)

TSO

Tesoro

$0.00

(0.00%)

WNR

Western Refining

$0.00

(0.00%)

T

AT&T

$37.90

-0.46 (-1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 23

    Oct

  • 24

    Oct

  • 31

    Oct

  • 12

    Nov

GLD

SPDR Gold Shares

$140.19

-1.14 (-0.81%)

17:58
09/13/19
09/13
17:58
09/13/19
17:58
Hot Stocks
SPDR Gold Shares holdings fall to 874.51MT from 880.37MT »

This is the second…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBVT

DBV Technologies

$10.22

0.595 (6.18%)

, AIMT

Aimmune

$24.66

(0.00%)

17:57
09/13/19
09/13
17:57
09/13/19
17:57
Hot Stocks
Breaking Hot Stocks news story on DBV Technologies, Aimmune »

DBV Technologies falls 2%…

DBVT

DBV Technologies

$10.22

0.595 (6.18%)

AIMT

Aimmune

$24.66

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Sep

AIMT

Aimmune

$24.66

(0.00%)

17:55
09/13/19
09/13
17:55
09/13/19
17:55
Hot Stocks
FDA committee votes to support use of Aimmune's Palforzia for peanut allergy »

Aimmune Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Sep

ZAYO

Zayo Group

$33.82

-0.05 (-0.15%)

17:39
09/13/19
09/13
17:39
09/13/19
17:39
Hot Stocks
Zayo Group CEO sells 1M common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

T

AT&T

$37.90

-0.46 (-1.20%)

, MO

Altria Group

$42.01

-0.77 (-1.80%)

17:38
09/13/19
09/13
17:38
09/13/19
17:38
Periodicals
CNN to longer run Juul ads, Daily Beast reports »

AT&T's (T) CNN…

T

AT&T

$37.90

-0.46 (-1.20%)

MO

Altria Group

$42.01

-0.77 (-1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

BAS

Basic Energy

$1.87

-0.08 (-4.10%)

17:34
09/13/19
09/13
17:34
09/13/19
17:34
Hot Stocks
Basic Energy CEO T.M. Patterson to leave company »

Basic Energy Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

XBIO

Xenetic

$1.61

-0.04 (-2.42%)

17:28
09/13/19
09/13
17:28
09/13/19
17:28
Syndicate
Breaking Syndicate news story on Xenetic »

Xenetic files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$218.71

-4.4 (-1.97%)

, DIS

Disney

$138.00

0.44 (0.32%)

17:22
09/13/19
09/13
17:22
09/13/19
17:22
Hot Stocks
Disney CEO Bob Iger resigns from Apple board of directors »

In a regulatory filing,…

AAPL

Apple

$218.71

-4.4 (-1.97%)

DIS

Disney

$138.00

0.44 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

PHG

Philips

$47.79

0.19 (0.40%)

17:21
09/13/19
09/13
17:21
09/13/19
17:21
Hot Stocks
Philips awarded maximum $400M Defense Logistics Agency contract »

Philips has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBSE

NeuBase Therapeutics

$5.70

-0.04 (-0.70%)

17:20
09/13/19
09/13
17:20
09/13/19
17:20
Syndicate
Breaking Syndicate news story on NeuBase Therapeutics »

NeuBase Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

KDMN

Kadmon

$2.80

-0.015 (-0.53%)

17:18
09/13/19
09/13
17:18
09/13/19
17:18
Syndicate
Breaking Syndicate news story on Kadmon »

Kadmon files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KDMN

Kadmon

$2.80

-0.015 (-0.53%)

17:18
09/13/19
09/13
17:18
09/13/19
17:18
Syndicate
Breaking Syndicate news story on Kadmon »

Kadmon files $200M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$198.82

1.22 (0.62%)

17:17
09/13/19
09/13
17:17
09/13/19
17:17
Hot Stocks
Raytheon awarded $427.3M Army procurement contract »

Raytheon was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.